Any progress in the management of advanced pancreatic cancer? Highlights from the "45th ASCO Annual Meeting". Orlando, FL, USA. May 29 - June 2, 2009

Journal of the Pancreas

Volumn 10, Issue 4, 2009, Pages 361-365

  Li, Jia ^a   Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Clinical trials as topic; Disease free survival; Eerlotinib; Gemcitabine; Pancreatic neoplasms; Surviva

Indexed keywords

AMG 655; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; ENDOTAG-1; ENOXAPARIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GV 1001; IRINOTECAN; MASITINIB; NAB PACLITAXEL; OXALIPLATIN; PEPTIDE VACCINE; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTICOAGULANT THERAPY; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CYTOPENIA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INOPERABLE CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PANCREAS CANCER; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PLATINUM; QUINAZOLINES; TREATMENT OUTCOME;

EID: 68649098097     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. National Cancer Institute, Surveillance Epidemiology and End Results. Pancreas. SEER Stat Fact Sheets (http://seer.cancer.gov/statfacts/html/ pancreas.html).
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6.
4. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, et al. A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas-GOIM/GISCAD/GOIRC) study. J Clin Oncol 2009; 27(15 Suppl.): Abstract 4504.
5. Buanes T, Maurel J, Liauw W, Hebbar M, Nemunaitis J. A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC). J Clin Oncol 2009; 27(15 Suppl.): Abstract 4601.
6. Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Marten A, Winkelmann, et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine: Interim toxicity analysis of a multicenter, randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2009; 27(15 Suppl.): Abstract 4604.
7. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-16.
8. Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007; 18:1652-9.
9. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8:82.
10. Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 2006; 95:1474-82.
11. Oh D, Lee K, Lee K, Sohn C, Park Y, Zang D, et al. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research. J Clin Oncol 2009; 27(15 Suppl.): Abstract 4607.
12. Cereda S, Rognone A, Ghidini M, Rezzonico S, Passoni P, Mazza E, et al. A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel. J Clin Oncol 2009; 27(15 Suppl.): Abstract 4614.
13. Fine R, Moorer G, Sherman W, Chu, Maurer KM, Chabot J, et al. Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol 2009; 27(15 Suppl.): Abstract 4623.
14. Kang SP, Saif MW. Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP. J Pancreas (Online) 2008; 9:83-90.
15. Hwang JY, Yoo C, Kim T, Lee J, Park D, Seo D, et al. A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy. J Clin Oncol 2009; 27(15 Suppl.): Abstract 4618.
16. Tang P, Gill S, Au HJ, Chen EX, Hedley D, Leroux M, et al. Phase II trial of erlotinib in advanced pancreatic cancer (PC). J Clin Oncol 2009; 27(15 Suppl.): Abstract 4609.
17. Van Cutsem E, Humblet Y, Gelderblom H, Vermorken JB, Vire Ft, Glimelius B, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic and efficacy data of a randomized study. 2007 ASCO Gastrointestinal Cancers Symposium. Abstract #237.
18. Kindler HL, Garbo L, Stephenson J, Wiezorek J, Sabin T, Hsu M, et al. A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). J Clin Oncol 2009; 27(15 Suppl.): Abstract 4501.
19. Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 2009; 27(15 Suppl.): Abstract 4525.
20. Loehr M, Bodoky G, Fölsch U, Märten A, Karrasch M, Lilla C, et al. Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: A phase II trial. J Clin Oncol 2009; 27(15 Suppl.): Abstract 4526.
21. Hammel P, Mornex F, Deplanque G, Mitry E, Levy P, Seitz J, et al. Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study. J Clin Oncol 2009; 27(15 Suppl.): Abstract 4617.
22. Fazal S, Saif MW. Supportive and palliative care of pancreatic cancer. JOP. J Pancreas (Online) 2007; 8:240-53.
23. Sohail MA, Saif MW. Role of anticoagulation in the management of pancreatic cancer. JOP. J Pancreas (Online) 2009; 10:82-7.
24. Riess H, Pelzer U, Deutschinoff G, Opitz B, Stauch M, Reitzig P, et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. J Clin Oncol 2009; 27(18 Suppl.): Abstract LBA4506.
25. Riess H, Pelzer U, Hilbig A, Stieler J, Opitz B, Scholten T, et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer. 2008 Dec 5;8:361.